Acutus Medical Inc
NASDAQ:AFIB
Intrinsic Value
Acutus Medical, Inc. engages in the development of medical devices and electrophy equipment. [ Read More ]
The intrinsic value of one
AFIB
stock under the Base Case scenario is
2.2324
USD.
Compared to the current market price of 0.1634 USD,
Acutus Medical Inc
is
Undervalued by 93%.
AFIB's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
AFIB or that its price is influenced by factors unrelated to fundamentals.
Acutus Medical Inc's market capitalization is 4.8m USD.
AFIB stock price is 0.1634 USD.
AFIB stock price (0.1634 USD) is 93% less than its Intrinsic Value (2.2324 USD).
AFIB. Open DCF Valuation
AFIB stock price (0.1634 USD) is 93% less than its Relative Value (2.2324 USD). Open Relative Valuation
AFIB has upside potential of 206% compared to the average analyst price target.
Open Wall St Estimates
AFIB's D/E (Debt to Equity) is equal to 1.1.
AFIB's Revenue has grown by an exceptional 25% over the past 12 months.
AFIB has negative Net Debt. This means that the company has more cash and short-term investments (38m USD) than debt (35m USD).
AFIB's long-term assets (85m USD) exceed its long-term liabilties (53m USD).
AFIB's ROE (Return on Equity) has significantly increased in the last 3 years from -191% to -73%, and is approaching profitability.
AFIB's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -226% to -169%, and is approaching profitability.
AFIB has negative Operating Income for the last twelve months.
AFIB has negative Net Income for the last twelve months.
AFIB's ROE (Return on Equity) for the past 12 months is negative and is equal to -73%.
AFIB's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -169%.
AFIB's Revenue is forecast to grow at a rate of 46% per year over the next 3 years.
AFIB has negative Gross Profit for the last twelve months.
AFIB's Revenue has been growing by an exceptional 50% per year for the last 3 years.
AFIB has negative Free Cash Flow for the last twelve months.
AFIB has negative three-year average ROE (Return on Equity): -108%. The company is not efficient at transforming stockholders' equity into net income.
AFIB has negative three-year average ROIC (Return on Invested Capital): -192%. The company is not efficient at using invested capital to generate operating income.
AFIB's short-term assets (73m USD) exceed its short-term liabilties (15m USD).
AFIB's Altman Z-Score is very low and is equal to -11.42.
AFIB doesn't generate enough operating income (-72m USD) to safely cover interest payments on its debt (5m USD).
Fundamental Analysis
Acutus Medical Inc
Balance Sheet Decomposition
Acutus Medical Inc
| Current Assets | 72.6m |
| Cash & Short-Term Investments | 38.5m |
| Receivables | 9m |
| Other Current Assets | 25.2m |
| Non-Current Assets | 12.1m |
| PP&E | 10m |
| Intangibles | 1.4m |
| Other Non-Current Assets | 688k |
| Current Liabilities | 14.8m |
| Accounts Payable | 4.8m |
| Accrued Liabilities | 7.8m |
| Other Current Liabilities | 2.2m |
| Non-Current Liabilities | 38.3m |
| Long-Term Debt | 34.8m |
| Other Non-Current Liabilities | 3.5m |
Earnings Waterfall
Acutus Medical Inc
|
Revenue
|
19.7m
USD
|
|
Cost of Revenue
|
-31.8m
USD
|
|
Gross Profit
|
-12.1m
USD
|
|
Operating Expenses
|
-59.7m
USD
|
|
Operating Income
|
-71.9m
USD
|
|
Other Expenses
|
39.1m
USD
|
|
Net Income
|
-32.8m
USD
|
Free Cash Flow Analysis
Acutus Medical Inc
AFIB Profitability Score
Profitability Due Diligence
Acutus Medical Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Acutus Medical Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
AFIB Solvency Score
Solvency Due Diligence
Acutus Medical Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Acutus Medical Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AFIB Price Targets Summary
Acutus Medical Inc
According to Wall Street analysts, the average 1-year price target for
AFIB
is 0.5 USD
.
Ownership
AFIB Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
AFIB Price
Acutus Medical Inc
| Average Annual Return | -45.92% |
| Standard Deviation of Annual Returns | 52.9% |
| Max Drawdown | -100% |
| Market Capitalization | 4.8m USD |
| Shares Outstanding | 29 716 000 |
| Percentage of Shares Shorted | 2.9% |
Company Profile
Acutus Medical Inc
Country
Industry
Market Cap
Dividend Yield
Description
Acutus Medical, Inc. engages in the development of medical devices and electrophy equipment. The company is headquartered in Carlsbad, California and currently employs 338 full-time employees. The company went IPO on 2020-08-06. The firm designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The Company’s lead product is its AcQMap imaging and mapping system, which offers a paradigm-shifting approach to mapping the drivers and maintainers of arrhythmias with unmatched speed and precision. The company designed AcQMap System to improve procedure efficiency and outcomes by rapidly and accurately identifying ablation targets and confirming both ablation success and procedure completion. Its AcQMap System consists of single-use AcQMap catheter, as well as its console, workstation and software algorithms.
You don't have any saved screeners yet
